Thiogenesis Therapeutics Corp. (TTI)
TSXV
0.5100
+0.0100 (+2.00%)
Closed
Oct 15, 2026
Day's Range
0.51000.5200
52 wk Range
0.44000.8100
Financial Statements - TTI - Thiogenesis Therapeutics Corp.
Revenue
0
Net Income
-7.42M▼ 136.1%
EBITDA
-7.31M▼ 91.9%
Free Cash Flow
-6.03M▼ 53.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-02-28 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -7.39M | -3.57M | -5.20M | -1.97M | -224.67K | -1.27M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -79.57K | 233.21K | -28.15K | -1.95M | - | 63.80K |
| Pre Tax Income | -7.42M | -3.14M | -5.06M | -3.92M | -224.45K | -1.21M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -7.42M | -3.14M | -5.06M | -3.92M | -224.45K | -1.21M |
| EPS Basic | -0.15 | -0.07 | -0.13 | -0.16 | -0.008042 | -0.043649 |
| EPS Diluted | -0.15 | -0.07 | -0.13 | -0.16 | -0.008042 | -0.043649 |
| Basic Shares Outstanding | 48.58M | 45.36M | 39.12M | 25.29M | 27.91M | 27.91M |
| Diluted Shares Outstanding | 48.58M | 45.36M | 39.12M | 25.29M | 27.91M | 27.91M |
| Ebit | -7.39M | -3.57M | -5.06M | -3.92M | -224.43K | -1.21M |
| Ebitda | -7.31M | -3.81M | -5.03M | -3.97M | -224.43K | -1.27M |
| Net Income Continuous Operations | -7.42M | -3.14M | -5.06M | -3.92M | -224.45K | -1.21M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
